MBIO 8-K SEC Filing Analysis

Latest settled — T+20d

MBIO ▼ -19.19% at T+20d

SHORT call ✓ call won +19.19% · α vs SPY +23.39% · entry $0.7400 → $0.5980

Next anchor: T+60d in 5w

Currently $0.7420 · -0.27% from $0.7400 entry (call sign-flipped)

Entry anchored
Apr 17, 12:31 PM ET
via Databento tick

T+1d

-3.24%

call +3.24% · α +2.59%

$0.7160

settled 7w ago

T+5d

+2.70%

call -2.70% · α -1.79%

$0.7600

settled 7w ago

T+20d

-19.19%

call +19.19% · α +23.39%

$0.5980

settled 26d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Mustang Bio (MBIO) received a Nasdaq delisting notice due to its stock trading below $1.00 for 30 consecutive days. The company has until October 12, 2026, to regain compliance, typically via a reverse stock split. Failure risks delisting, severely impacting liquidity for this $6M market cap biotech.

Actionable Insight

Monitor stock price closely through October 12, 2026. A reverse stock split announcement would be a temporary reprieve but dilutive. Delisting would severely impact liquidity and likely trigger further price declines. This is a high-risk situation for a micro-cap biotech with limited options.

Key Facts

Received Nasdaq delisting notice on April 15, 2026, for failing to maintain $1.00 minimum bid price
Has 180-day grace period until October 12, 2026, to regain compliance
Compliance can be achieved by maintaining a $1.00+ closing price for 10 consecutive business days
May pursue a reverse stock split if needed to regain compliance
Market cap is only $6M, indicating extreme financial distress

Financial Impact

High risk of delisting for a $6M market cap company; potential 90%+ decline if delisted to OTC market

liquidityshare priceinstitutional ownershipmarket capitalization

Risk Factors

Delisting from Nasdaq to OTC market, drastically reducing liquidity and institutional ownership
Reverse stock split would dilute existing shareholders and signal financial distress
Inability to raise capital or attract investors while under delisting threat

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001104659-26-044890
Document: 0001104659-26-044890-index-headers.html	0001104659-26-044890
Document: 0001104659-26-044890-index.html	0001104659-26-044890
Document: 0001104659-26-044890.txt	0001104659-26-044890

US Market Status

Market Closed — Opens Thu (10h 56m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access